Edwin Dejesus is an Infectious Disease physician affiliated with Orlando Immunology Center. OpenAlex indexes 217 publications with 19,387 citations (h-index 75); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Infectious Disease profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1707 N Mills Ave
Orlando, FL 328031851
Telephone
407-647-3960Provider last certified this registry record 8 May 2024.
Clinical trials
- Evolution of L74V or K65R Mutations in VIremic Subjects on Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) (EVITA)
Sponsor: Orlando Immunology Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20258 payments
- ViiV Healthcare CompanyProgram year202511 payments
- Theratechnologies Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
48.5%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor17.2%Tivicay84%Juluca16%Part D<11 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor11.3%Valacyclovir100%Part D≥15 patients+ 2 more classes in this area
Nervous system
29.4%Benzodiazepine10.9%Alprazolam58%Temazepam42%Part D<11 patientsGabapentinoids6.9%Pregabalin53%Gabapentin47%Part D<11 patients+ 3 more classes in this area
Genitourinary & hormones
9.9%Androgen9.9%Testosterone Cypionate63%Testosterone37%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
New England Journal of Medicine
2022
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”